Clinical trial
Phase 1b Open-Label, Dose-Identification Study of XPro1595 in Patients With Alzheimer's Disease and Biomarkers of Inflammation.
NCT03943264 is registered in ClinicalTrials.gov with Inmune Bio, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase 1b Open-Label, Dose-Identification Study of XPro1595 in Patients With Alzheimer's Disease and Biomarkers of Inflammation.
- Lead sponsor
- Inmune Bio, Inc.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- November 20, 2019
- Completion date
- September 1, 2021
- Enrollment
- 20 (actual)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.